Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping

M. Bulik, T. Kazda, P. Slampa, R. Jancalek,

. 2015 ; 2015 (-) : 641023. [pub] 20150913

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16028126

Grantová podpora
NT14120 MZ0 CEP - Centrální evidence projektů
NT14600 MZ0 CEP - Centrální evidence projektů

OBJECTIVE: To prospectively determine institutional cut-off values of apparent diffusion coefficients (ADCs) and concentration of tissue metabolites measured by MR spectroscopy (MRS) for early differentiation between glioblastoma (GBM) relapse and treatment-related changes after standard treatment. MATERIALS AND METHODS: Twenty-four GBM patients who received gross total resection and standard adjuvant therapy underwent MRI examination focusing on the enhancing region suspected of tumor recurrence. ADC maps, concentrations of N-acetylaspartate, choline, creatine, lipids, and lactate, and metabolite ratios were determined. Final diagnosis as determined by biopsy or follow-up imaging was correlated to the results of advanced MRI findings. RESULTS: Eighteen (75%) and 6 (25%) patients developed tumor recurrence and pseudoprogression, respectively. Mean time to radiographic progression from the end of chemoradiotherapy was 5.8 ± 5.6 months. Significant differences in ADC and MRS data were observed between those with progression and pseudoprogression. Recurrence was characterized by N-acetylaspartate ≤ 1.5 mM, choline/N-acetylaspartate ≥ 1.4 (sensitivity 100%, specificity 91.7%), N-acetylaspartate/creatine ≤ 0.7, and ADC ≤ 1300 × 10(-6) mm(2)/s (sensitivity 100%, specificity 100%). CONCLUSION: Institutional validation of cut-off values obtained from advanced MRI methods is warranted not only for diagnosis of GBM recurrence, but also as enrollment criteria in salvage clinical trials and for reporting of outcomes of initial treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16028126
003      
CZ-PrNML
005      
20241016141823.0
007      
ta
008      
161005e20150913xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2015/641023 $2 doi
024    7_
$a 10.1155/2015/641023 $2 doi
035    __
$a (PubMed)26448943
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bulik, Martin $u Department of Diagnostic Imaging, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic ; Department of Diagnostic Imaging, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic. $7 xx0323843
245    14
$a The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping / $c M. Bulik, T. Kazda, P. Slampa, R. Jancalek,
520    9_
$a OBJECTIVE: To prospectively determine institutional cut-off values of apparent diffusion coefficients (ADCs) and concentration of tissue metabolites measured by MR spectroscopy (MRS) for early differentiation between glioblastoma (GBM) relapse and treatment-related changes after standard treatment. MATERIALS AND METHODS: Twenty-four GBM patients who received gross total resection and standard adjuvant therapy underwent MRI examination focusing on the enhancing region suspected of tumor recurrence. ADC maps, concentrations of N-acetylaspartate, choline, creatine, lipids, and lactate, and metabolite ratios were determined. Final diagnosis as determined by biopsy or follow-up imaging was correlated to the results of advanced MRI findings. RESULTS: Eighteen (75%) and 6 (25%) patients developed tumor recurrence and pseudoprogression, respectively. Mean time to radiographic progression from the end of chemoradiotherapy was 5.8 ± 5.6 months. Significant differences in ADC and MRS data were observed between those with progression and pseudoprogression. Recurrence was characterized by N-acetylaspartate ≤ 1.5 mM, choline/N-acetylaspartate ≥ 1.4 (sensitivity 100%, specificity 91.7%), N-acetylaspartate/creatine ≤ 0.7, and ADC ≤ 1300 × 10(-6) mm(2)/s (sensitivity 100%, specificity 100%). CONCLUSION: Institutional validation of cut-off values obtained from advanced MRI methods is warranted not only for diagnosis of GBM recurrence, but also as enrollment criteria in salvage clinical trials and for reporting of outcomes of initial treatment.
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a nádory mozku $x diagnóza $x metabolismus $x terapie $7 D001932
650    _2
$a chemoradioterapie $x metody $7 D059248
650    _2
$a dakarbazin $x analogy a deriváty $x terapeutické užití $7 D003606
650    _2
$a zobrazování difuzních tenzorů $7 D056324
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a glioblastom $x diagnóza $x metabolismus $x terapie $7 D005909
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a molekulární zobrazování $x metody $7 D057054
650    _2
$a lokální recidiva nádoru $x diagnóza $x metabolismus $x prevence a kontrola $7 D009364
650    _2
$a hodnocení výsledků zdravotní péče $x metody $7 D017063
650    _2
$a prognóza $7 D011379
650    _2
$a protonová magnetická rezonanční spektroskopie $x metody $7 D066244
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kazda, Tomáš $u International Clinical Research Center, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic ; Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic ; Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. $7 xx0213412
700    1_
$a Šlampa, Pavel, $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic ; Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. $d 1960- $7 mzk2004257405
700    1_
$a Jančálek, Radim, $u International Clinical Research Center, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic ; Department of Neurosurgery, St. Anne's University Hospital Brno, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic ; Department of Neurosurgery, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic. $d 1975- $7 xx0037113
773    0_
$w MED00182164 $t BioMed research international $x 2314-6141 $g Roč. 2015 (20150913), s. 641023
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26448943 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20241016141818 $b ABA008
999    __
$a ok $b bmc $g 1166440 $s 952756
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 2015 $c - $d 641023 $e 20150913 $i 2314-6141 $m BioMed research international $n Biomed Res Int $x MED00182164
GRA    __
$a NT14120 $p MZ0
GRA    __
$a NT14600 $p MZ0
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace